The research carried out at Institute of Transfusion Medicine and Immunogenetics at Universitaet Ulm (IKT) focuses on cellular therapies, tumour immunology, molecular pathophysiology, and molecular diagnostics. IKT is a joint institute of the University Hospital Ulm and the German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen. The institute has extensive experience in the preparation of hematopoietic stem cells, adoptive immunotherapies for malignancies or infections, and BMC for a prospective, randomized, double-blind clinical trial for the treatment of myocardial infarction. More recently, they have been involved in the development of large-scale ex vivo expansion protocols for GMP-grade MSC.
Hubert Schrezenmeier has long-standing experience in development and characterisation of cellular therapy products. He has been work package leader in two European consortia on MSC (CASCADE: Cultivated Adult Stem Cells as Alternative for Damaged Tissue, Grant agreement no. 223236; and REBORNE: Regenerating Bone Defects Using New Biomedical Engineering Approaches, Grant agreement no. 241879). He is currently work package leader for the clinical-scale ex vivo MSC production for three ongoing clinical trials using MSC for various indications of bone repair. He has authored or co-authored more than 180 peer-reviewed publications on MSC, mechanisms and treatment of bone marrow failures, immunomodulation, and hematopoietic stem cell transplantation.